Shares of Dendreon popped nearly 10% Friday morning on news coming out of Europe. The CHMP, which is Europe's version of an FDA advisory committee, recommended that the biotech's prostate cancer vaccine, Provenge, be approved.
In this video, health care analyst David Williamson discusses what this recommendation means for Provenge's chances of approval, Dendreon's likely next move, and whether this will serve as a catalyst for shares going forward.
Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Predicting Dendreon's Next CEO's Future
Its time to play Fool in the blank
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.
Why Wall Street Hates Dendreon Corp.
Stocks with heavy short interest might signal that something is terribly wrong with a company. Dendreon Corp. sports one of the highest short interests among health-care stocks. Why are short-sellers so bearish on this small-cap biotech?